Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to assess efficacy and safety of the herbal medicinal product Sinupret extract coated tablets in patients with chronic rhinosinusitis

    Summary
    EudraCT number
    2015-001952-31
    Trial protocol
    DE  
    Global end of trial date
    23 Aug 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    06 Jan 2023
    First version publication date
    06 Jan 2023
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CRS-03
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Bionorica SE
    Sponsor organisation address
    Kerschensteinerstraße 11-15, Neumarkt, Germany, 92318
    Public contact
    Head of cooperate communication, Bionorica SE, info@bionorica.de
    Scientific contact
    Head of Research and Development, Bionorica SE, research.development@bionorica.de
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    19 Jun 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    23 Aug 2017
    Global end of trial reached?
    Yes
    Global end of trial date
    23 Aug 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the efficacy of the herbal medicinal product Sinupret extract versus placebo in the treatment of chronic rhinosinusitis (CRS) in adults.
    Protection of trial subjects
    This study was conducted in compliance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice, including the archiving of essential documents.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    28 Apr 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 363
    Country: Number of subjects enrolled
    Germany: 209
    Worldwide total number of subjects
    572
    EEA total number of subjects
    572
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    489
    From 65 to 84 years
    83
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    A total of 624 patients were enrolled; of these, 51 were not randomized and not treated. In total, 573 (91.8% of the enrolled population) patients were randomized, of whom 1 patient was not treated. In total, 285 patients were randomized to treatment with Sinupret extract (test IMP) and 287 patients to treatment with placebo.

    Pre-assignment
    Screening details
    The trial consists of a screening phase of up to 2 weeks (V1 to V2). Patients were required to have CRS symptoms for more than 52 weeks prior to enrolment, diagnosis of CRS confirmed by an ENT-specialist, and severe symptoms at screening and baseline (MSS of at least 10 points).

    Period 1
    Period 1 title
    Period 1 (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Placebo coated tablets
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One tablet placebo three times a day.

    Arm title
    Sinupret extract
    Arm description
    Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid.
    Arm type
    Experimental

    Investigational medicinal product name
    Sinupret extract
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid for 16 weeks.

    Number of subjects in period 1
    Placebo Sinupret extract
    Started
    287
    285
    End of treatment
    259
    257
    End of observation
    255
    252
    Completed
    255
    252
    Not completed
    32
    33
         Adverse event, serious fatal
    1
    -
         Consent withdrawn by subject
    11
    6
         Extreme CRS-related pain symptomatology
    2
    3
         Reasons not related to disease
    1
    1
         Adverse event, non-fatal
    11
    10
         Pregnancy
    -
    1
         Non-compliance with study drug
    1
    2
         Lost to follow-up
    4
    4
         Progressive disease
    1
    4
         Protocol deviation
    -
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo coated tablets

    Reporting group title
    Sinupret extract
    Reporting group description
    Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid.

    Reporting group values
    Placebo Sinupret extract Total
    Number of subjects
    287 285 572
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    244 245 489
        From 65-84 years
    43 40 83
        85 years and over
    0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    46.4 ( 14.73 ) 45.9 ( 14.06 ) -
    Gender categorical
    Units: Subjects
        Female
    168 164 332
        Male
    119 121 240

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo coated tablets

    Reporting group title
    Sinupret extract
    Reporting group description
    Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid.

    Subject analysis set title
    Sinupret extract - FAS
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All randomized patients with at least one documented application of IMP and with at least one observed post-baseline value for the primary efficacy variable (MSSINV).

    Subject analysis set title
    Placebo - FAS
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All randomized patients with at least one documented application of IMP and with at least one observed post-baseline value for the primary efficacy variable (MSSINV).

    Subject analysis set title
    Sinupret extract - SAF
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one dose of trial medication; patients who were treated with more than one type of clinical trial medication by mistake were analyzed according to the clinical trial medication they received the longest.

    Subject analysis set title
    Placebo - SAF
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one dose of trial medication; patients who were treated with more than one type of clinical trial medication by mistake were analyzed according to the clinical trial medication they received the longest.

    Subject analysis set title
    Sinupret extract - PPS
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All patients from the FAS without major protocol deviations.

    Subject analysis set title
    Placebo - PPS
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All patients from the FAS without major protocol deviations.

    Primary: MSS-INV

    Close Top of page
    End point title
    MSS-INV
    End point description
    The primary efficacy endpoint was the MSS-INV at V7.
    End point type
    Primary
    End point timeframe
    After 12 weeks of treatment (Visit 7).
    End point values
    Sinupret extract - FAS Placebo - FAS
    Number of subjects analysed
    279
    283
    Units: Score points
        arithmetic mean (standard deviation)
    5.4 ( 3.34 )
    5.6 ( 3.69 )
    Statistical analysis title
    Van Elteren test adjusted for centre
    Comparison groups
    Sinupret extract - FAS v Placebo - FAS
    Number of subjects included in analysis
    562
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3192
    Method
    Van Elteren test
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.73
         upper limit
    0.45

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All AEs ocurring between V2 (randomisation) and V8 (end of observation) are reported.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Sinupret extract
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    -

    Serious adverse events
    Sinupret extract Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 285 (1.05%)
    5 / 287 (1.74%)
         number of deaths (all causes)
    0
    1
         number of deaths resulting from adverse events
    0
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Parathyroid tumour benign
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Transient ischaemic attack
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Chest pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Meniere's disease
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung disorder
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Psychiatric disorders
    Adjustment disorder with depressed mood
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Hyperparathyroidism
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Pathological fracture
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Sinupret extract Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    113 / 285 (39.65%)
    116 / 287 (40.42%)
    Vascular disorders
    Circulatory collapse
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    2
    Hypertension
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Hypotension
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Thrombosis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Surgical and medical procedures
    Dental operation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Tooth extraction
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Asthenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Fatigue
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Malaise
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Mucosal dryness
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Oedema peripheral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Pyrexia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    2 / 287 (0.70%)
         occurrences all number
    1
    2
    Reproductive system and breast disorders
    Menstrual disorder
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Vulvovaginal inflammation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    4 / 287 (1.39%)
         occurrences all number
    3
    4
    Dysphonia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    2 / 287 (0.70%)
         occurrences all number
    0
    2
    Dyspnoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Epistaxis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    1 / 287 (0.35%)
         occurrences all number
    2
    1
    Nasal congestion
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Nasal obstruction
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Noninfective bronchitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Oropharyngeal pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    6 / 285 (2.11%)
    6 / 287 (2.09%)
         occurrences all number
    6
    7
    Pharyngeal inflammation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    2 / 287 (0.70%)
         occurrences all number
    1
    2
    Pharyngeal oedema
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Pleurisy
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Rhinalgia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Rhinorrhoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    3 / 287 (1.05%)
         occurrences all number
    3
    3
    Throat irritation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Upper respiratory tract inflammation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Insomnia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Product issues
    Device failure
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Investigations
    Alanine aminotransferase increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Blood alkaline phosphatase increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Blood creatine increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Blood glucose increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Blood urea increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Body temperature decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    C-reactive protein increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    2 / 287 (0.70%)
         occurrences all number
    0
    2
    Eosinophil count increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Gamma-glutamyltransferase increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    2 / 287 (0.70%)
         occurrences all number
    3
    2
    Haemoglobin decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Hepatic enzyme increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Lymphocyte count increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Neutrophil count decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Injury, poisoning and procedural complications
    Bone contusion
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Concussion
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Contusion
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    0 / 287 (0.00%)
         occurrences all number
    2
    0
    Fall
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Hand fracture
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Humerus fracture
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Ligament sprain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    2 / 287 (0.70%)
         occurrences all number
    2
    2
    Muscle injury
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Muscle strain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Nail injury
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Tendon rupture
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Thermal burn
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Tooth fracture
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Cardiac disorders
    Atrial fibrillation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Nervous system disorders
    Dizziness
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Dysgeusia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Headache
    alternative assessment type: Non-systematic
         subjects affected / exposed
    21 / 285 (7.37%)
    14 / 287 (4.88%)
         occurrences all number
    27
    17
    Migraine
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    1 / 287 (0.35%)
         occurrences all number
    3
    4
    Paraesthesia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Radiculopathy
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Sciatica
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Sensory disturbance
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Somnolence
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    1 / 287 (0.35%)
         occurrences all number
    4
    1
    Tension headache
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Trigeminal neuralgia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    2
    Blood and lymphatic system disorders
    Microcytic anaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Neutropenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Thrombocytopenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Thrombocytosis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Ear and labyrinth disorders
    Ear congestion
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Ear discomfort
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    1 / 287 (0.35%)
         occurrences all number
    2
    1
    Ear pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    1 / 287 (0.35%)
         occurrences all number
    2
    1
    Tinnitus
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Vertigo
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    1 / 287 (0.35%)
         occurrences all number
    3
    1
    Eye disorders
    Eye pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    3
    Ocular hyperaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Abdominal discomfort
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Abdominal distension
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Abdominal pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    4 / 287 (1.39%)
         occurrences all number
    1
    5
    Abdominal pain upper
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 285 (1.75%)
    6 / 287 (2.09%)
         occurrences all number
    5
    6
    Breath odour
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Colitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Diarrhoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    8 / 285 (2.81%)
    8 / 287 (2.79%)
         occurrences all number
    9
    9
    Diverticulum intestinal
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Dry mouth
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Dyspepsia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    3 / 287 (1.05%)
         occurrences all number
    2
    3
    Dysphagia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Flatulence
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    2 / 287 (0.70%)
         occurrences all number
    0
    2
    Food poisoning
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    1 / 287 (0.35%)
         occurrences all number
    2
    1
    Gastric disorder
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Gastritis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorder
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal inflammation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Gastrooesophageal reflux disease
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Haematochezia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Lip swelling
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Nausea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 285 (1.40%)
    0 / 287 (0.00%)
         occurrences all number
    4
    0
    Toothache
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Vomiting
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 285 (1.40%)
    0 / 287 (0.00%)
         occurrences all number
    4
    0
    Skin and subcutaneous tissue disorders
    Dermatitis allergic
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Erythema
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Hyperhidrosis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    8 / 285 (2.81%)
    0 / 287 (0.00%)
         occurrences all number
    8
    0
    Pruritus
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    2 / 287 (0.70%)
         occurrences all number
    1
    2
    Psoriasis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Rash
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Rash papular
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Rash pruritic
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Skin hypopigmentation
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Skin odour abnormal
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Urticaria
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    Haematuria
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Nephrolithiasis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Urine odour abnormal
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Back pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    2 / 287 (0.70%)
         occurrences all number
    0
    2
    Musculoskeletal stiffness
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Pain in extremity
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    2 / 287 (0.70%)
         occurrences all number
    0
    2
    Spinal pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Infections and infestations
    Acute sinusitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    2 / 287 (0.70%)
         occurrences all number
    1
    2
    Bronchitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    2 / 287 (0.70%)
         occurrences all number
    3
    2
    Bronchitis viral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Conjunctivitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Cystitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    4 / 287 (1.39%)
         occurrences all number
    3
    4
    Gastroenteritis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Gastroenteritis viral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Haemophilus infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Herpes zoster
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Influenza
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Laryngitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Nasal herpes
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Oral herpes
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    2 / 287 (0.70%)
         occurrences all number
    1
    2
    Pharyngitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    5 / 287 (1.74%)
         occurrences all number
    0
    6
    Pneumonia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Respiratory tract infection viral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 285 (0.70%)
    0 / 287 (0.00%)
         occurrences all number
    2
    0
    Rotavirus infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Sinusitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Skin infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Soft tissue infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Tonsillitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0
    Upper respiratory tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    6 / 285 (2.11%)
    4 / 287 (1.39%)
         occurrences all number
    7
    4
    Urinary tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 285 (1.05%)
    0 / 287 (0.00%)
         occurrences all number
    3
    0
    Viral infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    1 / 287 (0.35%)
         occurrences all number
    1
    1
    Viral pharyngitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Viral upper respiratory tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    29 / 285 (10.18%)
    32 / 287 (11.15%)
         occurrences all number
    30
    35
    Metabolism and nutrition disorders
    Fluid imbalance
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Hypercholesterolaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 285 (0.00%)
    1 / 287 (0.35%)
         occurrences all number
    0
    1
    Lactose intolerance
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 285 (0.35%)
    0 / 287 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 05:11:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA